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Abstract: A i m: the aim of this study was to assess the diagnostic value of hepatocyte growth factor 
(hgF) as a new predictor of severity in patients with acute pancreatitis (Ap) at early phase of disease.
M a t e r i a l s  a n d  M e t h o d. The studied group involved 40 patients (16 women and 24 men) with 
Ap admitted to Ist Dept. of Surgery Jagiellonian University Medical College in Krakow. Twenty-four 
patients had mild and twelve severe form of Ap. glasgow and Imrie scores were calculated to evaluate 
severity of AP. HGF concentrations were measured by ELISA (R&D Systems) on days 1, 3 and 5 after 
admission within 48 hours after onset of symptoms. 
R e s u l t s: Serum median concentrations of hgF was significantly higher in patients with severe 
versus mild clinical course of AP on each of the study days (7.61 vs 3.30 ng/mL, p = 0.05 on day 1; 
7.19 vs 3.43, p = 0.04 on day 3 and 5.76 vs 2.42, p = 0.02 on day 5). HGF positively correlated 
with Glasgow and Imrie scores (R = 0.57 and R = 0.51). HGF negatively correlated with fetuin A, 
a negative acute phase protein (R = –0.60 on day 3 and R = –0.45 on day 5) and positively with CRP 
(R = 0.93; R = 0.80), SAA (R = 0.78; R = 0.82), IL-6 (R = 0.61; R = 0.77; R = 0.85 on day 1, 3 and 5, 
respectively) and PMN-elastase (R = 0.58; R = 0.64; R = 0.77). On day 1 of the study, HGF reached 
the diagnostic sensitivity of 100% and specificity of 50% for the detection of severe and moderate AP.
C o n c l u s i o n s: Serum hgF correlates with several inflammatory markers and clinical scores (glas-
gow, Imrie) in patients with Ap and may be considered a new promising tool in assessing the severity 
of acute pancreatitis. 
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INtRODuCtION
Despite recent advances in medical sciences, acute pancreatitis (Ap) is still as-
sociated with severe complications resulting in high mortality (20–30%) [1–2]. 
It is necessary to evaluate the severity of AP and the risk of life-threatening 
complications at early phase [1, 3–4]. In 1996, Ueda et al. [5] have shown high 
hepatocyte growth factor (hgF) concentrations in patients with organ (liver, kid-
ney, or lung) dysfunction.
hgF, also known as hepatotrophin, is a multifunctional cytokine involved 
in cell proliferation, differentiation and migration as well as angiogenesis. hgF 
is produced and delivered to injured tissues via systemic (endocrine) and local 
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(paracrine) mechanism and acts on various types of cells through its receptor 
c-Met [3, 6]. HGF serum concentration significantly increases in the course of 
acute inflammation, such as sepsis or viral infection (e.g. viral hepatitis). As 
other growth factors, HGF secretion is regulated by pro-inflammatory cytokines, 
including interleukin 6 (IL-6) that also stimulates acute phase proteins synthesis, 
regeneration of hepatocytes, as well as proliferation and differentiation of mega-
karyocytic hematopoietic cells and T and B lymphocytes [5–7].
HGF is a potent anti-inflammatory agent suppressing NF-kB activation in 
numerous types of cells, including macrophages (i.e. induces macrophage differ-
entiation with an anti-inflammatory phenotype — type M2) and lymphocytes and 
inhibiting LPS-mediated production of pro-inflammatory cytokines such as tumor 
necrosis factor a (TNF-a), IL-1b, IL-6 and IL-18 [6–8]. Sanada et al. [9] showed 
that HGF exert an anti-oxidant effect on vascular smooth muscle cells (VSMCs). 
HGF might represent a novel integrated multiple-target approach to suppress in-
flammation and to lower the risk of complications from inflammatory injury [10].
the aim of this study was to assess diagnostic value of hgF as a predictor 
of severity in patients with Ap at early phase of disease.
MAtERIALS AND MEthODS
StuDIED gROup
the studied group involved 28 patients with mild (MAp) and 12 with severe and 
moderate form of Ap (SAp) admitted to the Ist Department of general and gastro-
intestinal Surgery, Jagiellonian university Medical College in Krakow. All patients 
in the studied group were admitted to the hospital within 48 hours following the 
onset of acute disease signs and symptoms. A diagnosis of Ap was established 
based on clinical history, ultrasound scan and serum amylase/lipase activity (at 
least three times above the reference limit). the progression of morphological 
changes within the pancreas and in the surrounding tissues was evaluated using 
ultrasound imaging. In all patients ultrasound was performed every day during 
the study period. All patients with the moderate and severe form of Ap unde-
rwent computed tomography (Ct). In a few cases, the Ct was performed more 
than once and showed the evolution of necrotic changes in the parenchyma of 
the pancreas and in the retroperitoneal and peritoneal spaces. the severity of Ap 
was determined according to clinical and laboratory parameters; AP classification 
met the Atlanta criteria revised in 2012 [11]. Patients with formerly diagnosed 
liver or kidney failure and patients who refused to give the informed consent 
were excluded. 
the study protocol has been approved by Jagiellonian university Medical Col-
lege Bioethics Committee (KBET/86/B/2012). The study was conducted in ac-
cordance with the Declaration of helsinki. 
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Demographic characteristics were presented in table 1.
t a b l e  1
Characteristics of studied groups in terms of sex and age.
group n
Sex, n (%) Age (years) 
mean ± SDwomen Men
MAp 28 14 (50%) 14 (50%)  51,8 ± 15,3*
SAp 12     2 (16,6%)    10 (83,3%)  42,1 ± 11,5*
total 40 16 (40%) 24 (60%) 46,9 ± 13,4
MAP — mild acute pancreatitis; SAP — severe and moderate acute pancreatitis; n — number of patients; *p <0.05
LABORAtORy MEthODS
Median and range values of hgF in patients with MAp and SAp were determined 
in samples collected on day 1, day 3 and day 5 of hospitalization (Table 2). The 
samples were taken together with the blood used for routine biochemical tests in 
order to avoid additional burden for the patients. twenty minutes after drawing, 
the blood was centrifuged (4000 rotations/minute; 10 minutes), the serum was 
frozen and kept in temperature –70oC until measured. the measurements were 
carried out when all the samples have been collected. the following methods 
were used:
— Interleukin 6, soluble TNFa receptor II (sTNFRII) and HGF: ELISA with 
the use of R&D Systems kits (Minneapolis, uSA). the reference intervals 
established for these methods (manufacturer’s information) were: 0.70–
12.5 pg/mL for IL-6; 1.0–3.17 ng/mL for sTNFRII and 0.67–1.99 ng/mL 
for hgF, respectively.
— Fetuin A and PMN-elastase: ELISA with the use of BioVendor kits (Brno, 
Czech Republic). The reference range established for fetuin A was 0.260–
0.348 g/L, according to author’s study. The reference interval for PMN-ela-
stase was 25.8–48.6 ng/mL for PMN-elastase, according to the manufacturer. 
t a b l e  2
HGF serum concentration in patients with MAP and SAP during 5 days of observation.
Day of study MAp SAp p
day 1 3.30 (2.28–5.20) 7.61 (4.49–8.17) 0.05
day 3 3.44 (2.29–6.26)   7.20 (4.92–10.22) 0.04
day 5 2.42 (2.00–4.93) 5.76 (3.37–8.58) 0.02
HGF — hepatocyte growth factor; MAP — mild acute pancreatitis; SAP — severe and moderate acute pancreatitis
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Interleukin 18 (IL-18): ELISA with use of MBL kits (Nagoya, Japan). The refe-
rence range established for this method was 36.1–257.8 pg/mL (manufacturer’s 
information). 
The measurements of all ELISA micro-plates were performed using Automatic 
Reader BIO-TEK® Instruments, Inc., USA. 
Serum amylase, cholinesterase (ChE), aspartate aminotransferase (ASt) acti-
vities as well as albumin concentrations were measured with Modular p Clinical 
Analyzer (Roche Diagnostica, Mannheim, Germany). Reference range values for 
serum amylase ranged from 62 to 220 U/L, for CHE 5320–12920 U/L, for AST 
from 10–37 U/L and for albumin 35–50 g/L. CRP and serum amyloid A (SAA) 
concentrations were measured using immunonephlometric method on Nephe-
lometer BN II (Siemens Healthcare Diagnostics, Germany); the reference range 
for SAA was <6.40 mg/L (the lower detection limit was 0.8 mg/L) and for CRP 
0.16–5.0 mg/L. Hematology parameters were measured using the Sysmex XE 
2100 Hematological Analyzer (Sysmex Corp., Japan).
StAtIStICAL ANALySIS
Data are presented as mean ± SD for normally distributed variables and median 
(lower-upper quartile) for non-normal distributed variables (p <0.05 in Kolmo-
gorov–Smirnov test for normality). Mann–Whitney U test was used to assess 
differences between MAp and SAp groups. Correlations between variables were 
assessed with Spearman rank coefficients. The cut-off value together with diagno-
stic sensitivity and specificity for the prediction of SAp were assessed using the 
receiver operating characteristic (ROC) analysis. A value of p <0.05 was consi-
dered statistically significant. Statistical analysis was performed using statistical 
package Statistica 9.0 (Statsoft Inc. Tulsa, USA).
RESuLtS
Mean hospital stay of patients with diagnosis of moderate and severe acute pan-
creatitis was 20 (12–47) days and was statistically significantly longer compared 
to patients with mild form of disease (6 (5–8) days; p = 0.01).
DIAgNOStIC utILIty OF hgF IN Ap
Serum hgF concentrations were significantly higher in severe and moderate than 
in mild Ap on each of the study days (table 2). Based on ROC analysis, hgF 
cut-off value for detecting SAP was 3.28 ng/mL on day 1 of the study. Diagnostic 
sensitivity and specificity equaled 100% and 50%, respectively and area under the 
ROC curve was 0.75 (Figure 1). Additionally, HGF concentrations in patients with 
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Fig. 1. ROC curve showing the diagnostic performance of hgF measured on the day 1 of the study 
for the detection of SAP. HGF concentration at the chosen cut-off point is shown on the graph. 
HGF — hepatocyte growth factor; SAP — severe and moderate acute pancreatitis
SAP were more than 3-fold higher on the days 1 and 3, and 2-fold higher on the 
day 5 of the study when compared to the values obtained in healthy population. 
RELAtIONShIp BEtwEEN hgF AND CLINICAL SEVERIty SCORES
During first 48 hours, hgF concentration significantly correlated with both glas-
gow (R = 0.57; p = 0.007) and Imrie (R = 0.51; p = 0.02) scores routinely used 
for assessing prognosis in Ap. Average values for each prognostic scale in patients 
with SAp and MAp are show in table 3. Score greater than 3 in the glasgow and 
Imrie scale were found in 3 patients (25%) of the SAP group. Both scales had 
t a b l e  3
glasgow and Imrie scores in severe and mild Ap patients.
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a low diagnostic sensitivity rate of 25% and maximal 100% specificity at cut-off 
value of 3 points. 
RELAtIONShIp BEtwEEN hgF AND INFLAMMAtORy MARKERS
Positive correlation between HGF and interleukin 6 concentration was significant 
already on the first day of the study (i.e. at the time of admission to the ward) 
and it was even stronger on days 3 and 5. Also, positive correlations were noted 
between HGF concentration and direct neutrophil count as well as PMN-elastase 
concentration (table 4). On day 3 after admission to hospital, hgF concentra-
tions correlated positively with most of the inflammatory markers studied: IL-6, 
soluble tNFRII, SAA, CRp and direct monocyte count. Correlation between hgF 
concentration and total white blood cells count was observed on the day 5 of 
the study. Statistically significant negative correlation was noted between hgF 
levels and negative acute phase proteins (fetuin A and albumin) as well as cho-
linesterase activity (table 4).
t a b l e  4
the most important statistically significant correlations between hgF and selected hematological 
and biochemical markers in patients with AP during consecutive 5 days of observation.
parameter
Spearman correlation coefficient R (p < 0.05)
Days of observation
Day 1 Day 3 Day 5
CRp NS   0.93   0.80
SAA NS   0.78   0.82
stNFRII NS   0.48   0.61
Fetuin A NS –0.60 –0.45
Albumin NS –0.72 NS
IL-6 0.61   0.77   0.85
IL-18 NS NS   0.62
wBC NS NS   0.74
Neutrophil direct count 0.47   0.46   0.74
Monocyte direct count NS   0.45   0.76
N/L ratio 0.54   0.45   0.70
PMN-elastase 0.58   0.64   0.77
Amylase NS NS   0.57
ASt NS NS   0.75
ChE NS –0.81 –0.57
IL-6 — interleukin 6; CRP — C reactive protein; SAA — serum amyloid A; sTNFRII — soluble TNFa receptor; WBC — 
white blood cells; CHE — cholinesterase; PMN-elastase — polymorphonuclear elastase; AST — aspartate amino-
transferase; IL-18 — interleukin 18; N/L ratio — neutrophils/lymphocytes ratio; NS — not statistically significant
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DISCuSSION
According to the newest 2012 revision of Atlanta classification, acute pancreati-
tis begins at the time of the onset of pain in patient and its course may include 
two phases: the early phase comprises the first week of the disease (maximum 
10 days) and the late phase may last for several weeks or even months [11]. 
During the first 7 days of Ap, it is recommended to start the appropriate thera-
peutic interventions within the first 48 hours (“therapeutic window”) to lower the 
risk of complications [1, 11–14]. Consequently, the diagnostic tests that help 
predict the severity of Ap should be offered within this first 48 hours of disease. 
Studies in this area included early acute phase markers such as TNF-a (tumour 
necrosis factor-alpha), IL-1b, IL-6, IL-8, PAF (platelet activating factor) and MCP-
1 (monocyte chemoattractant protein 1) as well as adhesion molecules ICAM-1 
(intracellular adhesion molecule 1) and selectins, however, laboratory techniques 
used (based on ELISA) may significantly reduce their availability [14]. CRP is 
used as a gold standard marker, but its most significant increase in Ap is noted 
after about 72 hours from the onset of the disease [3]. About 12 hours before 
CRp, a peak in SAA concentration is observed, however SAA testing is much less 
popular and offered only by selected laboratories [15]. Both acute phase proteins 
mentioned show significant correlations with numerous inflammatory markers, 
including HGF. According to Ueda et al. [16], serum HGF is as useful as C-re-
active protein and more useful than IL-6 for detecting severe pancreatitis and for 
predicting hepatic dysfunction [16]. Also, correlation between plasma HGF level 
and the severity of AP has been observed in animal models [4]. Pancreatitis as-
sociated elevations in hgF suggest that adhesion molecules and growth factors 
could be the markers of AP. According to Warzecha et al. [4], HGF is not only 
a marker of acute inflammation but also a result of pancreatitis and the increase 
in HGF levels during inflammation plays a role in self-defense mechanism reduc-
ing tissue damage. Pezzilli et al. [17] and Barassi et al. [18] confirmed that HGF 
levels in Ap patients are higher comparing to healthy population and that peak 
levels are observed after 2 days of disease. however, in these studies hgF con-
centration was not useful to predict the severity of Ap. to the contrary, in our 
study hgF levels were significantly increased already on the first day of Ap, and 
SAp patients presented higher levels than those with MAp (table 3). Our results 
are consistent with the study of Pezzilli et al. [17] that showed HGF levels about 
3-times higher in AP patients comparing to controls.
CONCLuSIONS
Serum hgF correlates with several inflammatory markers and clinical scores 
(glasgow, Imrie) in patients with Ap and can be considered as a new promising 
tool in assessing severity of acute pancreatitis.
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